



## Company Overview

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company's development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

## Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Mar 9 2026, 7:30 AM EDT

## Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

Mar 3 2026, 7:30 AM EST

## Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 9 2026, 10:04 AM EST

## Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	257.95m
Last Price	\$4.76
52-Week	\$3.9328 - \$7.5401

03/13/2026 08:00 PM EDT

## Investor Relations

[ir@abeonatherapeutics.com](mailto:ir@abeonatherapeutics.com)

## Management Team

### Vishwas Seshadri, Ph.D., M.B.A.

Chief Executive Officer, Director

### Alison Hardgrove, J.D., M.B.A

Chief People Officer

### Brian Kevany, Ph.D.

Chief Technical Officer & Chief Scientific Officer

### Brendan O'Malley, J.D., Ph.D.

Chief Legal Officer

### Mohamad Tabrizi, M.S., M.B.A.

Chief Business Officer

### Madhav Vasanthavada, Ph.D., M.B.A.

Chief Commercial Officer

### Joseph Vazzano

Chief Financial Officer

### Megan Callan

VP, Head of Quality

### Carl Denny

SVP, Regulatory Affairs

### Greg Gin

VP, Investor Relations and Corporate Communications

### James Gow, MD, MBA, MS, MHCM

SVP, Clinical Development & Medical Affairs

### Amanda Moore, MSHS

VP, Head of Program Leadership

---

## Abeona Therapeutics Inc.

6555 Carnegie Avenue  
4th Floor  
Cleveland, OH 44103

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.